NCT02790671已完成1 期
An Open-Label, One-Sequence, Two-Period Study to Evaluate the Effects of Itraconazole on the Pharmacokinetics of DS-8500a in Healthy Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 26
- 试验地点
- 1
- 主要终点
- Area under the concentration curve (AUC) of DS-8500a
研究概览
简要总结
Study will assess the effects of itraconazole on the pharmacokinetic (PK) parameters of single-dose DS-8500a in healthy subjects. This is an open-label study in healthy subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male and female subjects between 18 and 45 y of age, with a Body-Mass Index (BMI) of 18 kg/m2 to 30 kg/m2, inclusive, at Screening.
- •Good health as determined by evaluations performed at Screening and during Enrollment on Day -
- •Negative serum pregnancy test at Screening and a negative urine pregnancy test during Enrollment on Day -1 for all female subjects. Additionally, female subjects must be:
- •Surgically sterile (ie, bilateral tubal ligation or removal of both ovaries and/or uterus at least 6 mo prior to dosing)
- •Naturally postmenopausal (spontaneous cessation of menses) for at least 24 consecutive mo prior to dosing, with a follicle stimulating hormone (FSH) level at Screening of ≥ 40 mIU/mL
- •Non-lactating
- •Male subjects must agree to contraception (condom with spermicide) in addition to having their female partner (if of childbearing potential) use another form of contraception (eg, an intrauterine device, diaphragm with spermicide, oral contraceptive, injectables, or subdermal hormonal implant) from the first dose until 12 wk following last administration. Also, male subjects must not donate sperm during the study and afterwards for a period of 12 wk.
- •Provided written informed consent prior to participating in the study. Able to understand and willing to comply with all the study requirements, and willing to allow the collection of all blood and urine specimens.
- •Negative urine test for drugs of abuse (opiates, benzodiazepines, amphetamines, cannabinoids, cocaine, barbiturates, phencyclidine), cotinine, and alcohol at Screening and During Enrollment on Day -
- •Willingness to abstain from grapefruit/grapefruit juice and Seville oranges 10 d before the first dose of study drug on Day 1 until the end of the study on Day
- •Willingness to refrain from consuming food or beverages containing caffeine/xanthine and alcohol 24 h prior to Enrollment on Day -1 until the end of the study on Day 31.
排除标准
- •History or current evidence of clinically significant cardiac, hepatic, renal, pulmonary, endocrine/metabolic, neurologic, infectious, gastrointestinal (ie, any condition which may affect drug absorption), hematologic, or oncologic disease.
- •Laboratory results (serum chemistry, hematology, and urinalysis) outside of the normal range and considered clinically significant in the opinion of the PI. Liver function (AST, ALT, bilirubin) test results must be below the ULN at Screening and during Enrollment on Day -
- •A QTcF interval duration > 450 msec at Screening.
- •Participation in a previous DS-8500a study, or dosing with itraconazole, within 6 mo prior to the first dose.
- •Known sensitivity to product components of DS-8500a and/or itraconazole.
- •Current participation in another investigational study or prior participation in an investigational study within the past 30 d prior to the first dose.
- •Use of any prescription or over-the-counter (OTC) medications (systemic or topical), vitamins, or dietary/herbal supplements, including St John's Wort (hypericin), within 14 d prior to the first dose.
- •Consumption of more than 28 units of alcohol per wk (males) or 14 units of alcohol per wk (females), where 1 unit of alcohol equals 1/2 pint of beer, 4 ounces of wine, or 1 ounce of spirits, or significant history of alcoholism or drug/chemical abuse within the last 2 y.
- •Use of tobacco products or nicotine-containing products, including smoking cessation aids, such as gums or patches, within 6 mo prior to the first dose.
- •Positive test result for HBsAg, HCV, or HIV antibody.
- •Employment by the clinic.
- •Familial relationship (spouse and/or first degree relative) with another study participant.
- •Any other reason that, in the opinion of the PI, precludes subject participation in the study.
研究组 & 干预措施
single study arm
Experimental
DS-8500a and itraconazole
干预措施: DS-8500a (Drug)
single study arm
Experimental
DS-8500a and itraconazole
干预措施: Itraconazole (Drug)
结局指标
主要结局
Area under the concentration curve (AUC) of DS-8500a
时间窗: Day 1 to Day 6
To assess the effects of itraconazole on the pharmacokinetic (PK) parameters of single-dose DS-8500a
maximum concentration (Cmax) of DS-8500a
时间窗: Day 1 to Day 6
To assess the effects of itraconazole on the pharmacokinetic (PK) parameters of single-dose DS-8500a
time of maximum concentration (Tmax) of DS-8500a
时间窗: Day 1 to Day 6
To assess the effects of itraconazole on the pharmacokinetic (PK) parameters of single-dose DS-8500a
次要结局
- change in 12-lead electrocardiogram(Day 1 to Day 31)
- Number and severity of adverse events(Day 1 to Day 31)
- change in physical examination findings(Day 1 to Day 31)
- change in clinical laboratory test results(Day 1 to Day 31)
- change in vital sign measurements(Day 1 to Day 31)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Study of GSK3511294 in Healthy Chinese ParticipantsAsthmaNCT05140200GlaxoSmithKline20
已完成
1 期
Study to Assess the Safety and PK of Oral and IV Xenleta in Adults With Cystic FibrosisCystic FibrosisNCT05225805Nabriva Therapeutics AG13
终止
1 期
Phase 1b Study of Tizanidine in Pediatric Patients With Cerebral PalsySpasticity Due to Cerebral PalsyNCT01405950Acorda Therapeutics10
已完成
2 期
Study to Assess the Safety and Pharmacokinetics of AKB-6548 in Participants With Chronic Kidney Disease (CKD), Stages 3 and 4Chronic Kidney DiseaseNCT04707573Akebia Therapeutics22
已完成
1 期
Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2001 in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN) and Patients With Transthyretin Amyloidosis-Related Cardiomyopathy (ATTR-CM)NCT04601051Intellia Therapeutics72